Novo Nordisk to Present Hemophilia Portfolio and Pipeline Data at 56th American Society of Hematology Meeting

News provided by

Dec 01, 2014, 08:55 ET

PLAINSBORO, N.J., Dec. 1, 2014 /PRNewswire/ -- Novo Nordisk will unveil 11 abstracts containing safety and efficacy data from its hemophilia portfolio and pipeline at the 56^th Annual Meeting of the American Society of Hematology (ASH), which will be held December 6–9 in San Francisco, CA. Following is a selection of the abstracts that will be presented:

Changes in annualized bleeding rate over time and relationship with dosing of turoctocog alfa during the guardian™ program (Poster Number: 2850)
Safety, efficacy, and pharmacokinetics of nonacog beta pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously treated pediatric hemophilia B patients (Poster Number: 1513)
Safety and efficacy of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in previously treated patients with hemophilia B: Results from an extension trial (Poster Number: 2846)
Impact of Glanzmann's Thrombasthenia: Perceptions from US patients and parents (Poster Number: 4853)
Unmet needs in diagnosis and treatment of Glanzmann's Thrombasthenia: Perceptions of US hematologists and nurses (Poster Number: 2179)

A complete listing of abstracts being presented and published at ASH can be accessed here.

"Novo Nordisk is excited to present such a robust data set at this year's ASH Annual Meeting and to continue to make important contributions to the body of scientific knowledge available on hemophilia and other rare bleeding disorders," said Stephanie Seremetis, M.D., CMO and CVP, Hemophilia, Novo Nordisk. "We seek to continuously advance the development of new therapies to benefit the bleeding disorders community."

Indications and Usage for Novoeight^® (Antihemophilic Factor [Recombinant])
Novoeight^® is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight^® when you have surgery.

Novoeight^® is not used to treat von Willebrand Disease.

Important Safety Information for Novoeight^®You should not use Novoeight^® if you are allergic to factor VIII or any of the other ingredients of Novoeight^® or if you are allergic to hamster proteins.

Call your healthcare provider right away and stop treatment if you get any of the following signs of an allergic reaction: rashes or hives, difficulty breathing or swallowing, tightness of the chest, swelling of the lips and tongue, light-headedness, dizziness or loss of consciousness, pale and cold skin, fast heartbeat, or red or swollen face or hands.

Before taking Novoeight^®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII.

Your body can make antibodies called "inhibitors" against Novoeight^®, which may stop Novoeight^® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Novoeight^®.

Common side effects of Novoeight^® include swelling or itching at the location of injection, changes in liver tests, and fever.

For full Prescribing Information, please click here.

About Novoeight^®
Novoeight^®is approved by the US Food and Drug Administration (FDA) (October 2013) and the European Medicines Agency (November 2013) for the treatment and prophylaxis of bleeding in patients with hemophilia A. Novoeight^®also is approved in Japan (January 2014), Australia (January 2014), and Switzerland (February 2014), and applications for regulatory approvals have been submitted in a range of other countries.

About N9-GP
N9-GP is an extended half-life recombinant coagulation Factor IX derivative intended to offer prophylaxis and treatment of bleeds in patients with hemophilia B. N9-GP is an investigational product and is not approved by the FDA.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy, and hormone replacement therapy. For more information, visit www.novonordisk-us.com or follow our news in the United States on Twitter: @novonordiskus.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novo-nordisk-to-present-hemophilia-portfolio-and-pipeline-data-at-56th-american-society-of-hematology-meeting-300001281.html

SOURCE Novo Nordisk